Targeted drugs for the latest treatment of renal pelvis cancer include small molecule tyrosine kinase inhibitors, large molecule monoclonal antibody targeted drugs and mTOR inhibitors targeted drugs. 1. Small molecule tyrosine kinase inhibitors mainly inhibit the activity of tyrosine kinase, thus blocking the signaling and inhibiting the growth of cancer cells, commonly used drugs include sunitinib, sorafenib, axitinib and so on. 2. At present, large molecule monoclonal antibody targeted drugs used in the treatment of renal pelvis cancer mainly refer to bevacizumab, which plays a therapeutic role by inhibiting tumor neoangiogenesis in renal pelvis cancer. 3. mTOR inhibitor targeted drugs used in the treatment of renal pelvis cancer mainly refer to everolimus, which plays an anti-cancer role by inhibiting the growth and proliferation of tumor cells. Targeted drugs should be used under the guidance of doctors after genetic testing to determine whether there is any corresponding target point and should not be used blindly, and if there is any discomfort during the use of drugs, consult the doctor in time to avoid delaying the condition.